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Lifetime effects, costs, and cost effectiveness of testing for human
papillomavirus to manage low grade cytological abnormalities:
results of the NHS pilot studies
Rosa Legood, Alastair Gray, Jane Wolstenholme, Sue Moss
Abstract
Objectives To predict the incremental lifetime effects, costs, and
cost effectiveness of using human papillomavirus testing to
triage women with borderline or mildly dyskaryotic cervical
smear results for immediate colposcopy.
Design Modelling study.
Setting Three centres participating in NHS pilot studies, United
Kingdom.
Population Women aged 25-64 with borderline or mildly
dyskaryotic cervical smear results.
Interventions Screening using conventional cytology, liquid
based cytology, and four strategies with different age cut-off
points and follow up times that used combined liquid based
cytology and human papillomavirus testing (adjunctive human
papillomavirus testing).
Results The model predicts that compared with using
conventional cytology without testing for human
papillomavirus, testing for the virus in conjunction with liquid
based cytology for women with borderline or mildly dyskaryotic
cervical smear results (aged 35 or more) would cost £3735
(euros5528; $6474) per life year saved. Extending adjunctive
human papillomavirus testing in combination with liquid based
cytology to include women aged between 25 and 34 costs an
additional £4233 per life year saved. Human papillomavirus
testing is likely to reduce lifetime repeat smears by 52%-86%
but increase lifetime colposcopies by 64%-138%.
Conclusions Testing for human papillomavirus to manage all
women with borderline or mildly dyskaryotic cervical smear
results is likely to be cost effective. The predicted increase in
lifetime colposcopies, however, deserves careful consideration.
Introduction
Human papillomavirus is present in virtually all cases of cervical
cancer.1 Testing for the virus could be incorporated in a cervical
cancer screening programme to stratify women with minor cyto-
logical abnormalities for immediate colposcopy.2 3 In the United
Kingdom, women with borderline or mildly dyskaryotic cervical
smear results are recalled for repeat smears every six months and
only return to routine screening intervals after three consecutive
negative test results. The disadvantages of this approach
compared with testing for human papillomavirus are potentially
missing lesions that could be treated earlier, the costs incurred by
patients and the healthcare system, and the failure of women to
attend for repeat tests.
In 2000-1 the Department of Health established a series of
pilot sites to assess both liquid based cytology and human papil-
lomavirus testing of women with borderline or mildly dyskaryo-
tic smear results. Three laboratories were selected after a
competitive process and converted to using liquid based cytology
to prioritise women for immediate referral for colposcopy. The
Department of Health policy research programme commis-
sioned an independent evaluation of these pilots. The clinical
and epidemiological outcomes observed at 12 months are
presented elsewhere.4
We compared the lifetime effects, costs, and cost effectiveness
of using cytology alone with using combined cytology and triage
on the basis of human papillomavirus testing to manage women
with borderline and mildly dyskaryotic smear results in the
United Kingdom. We used the current policy of screening
women aged 25-49 every three years and women aged 50-64
every five years.
Methods
We used the final results of the NHS pilot studies, including clini-
cal, epidemiological, and cost data. As no long term follow-up
data are available, we used a mathematical model to estimate the
lifetime effects, costs, and cost effectiveness. We used an adapted
version of a prior natural history model developed using a
Markov process in Data 4.0 (Treeage software; Williamstown,
MA).5 Our model predicted the lifetime costs and effects of alter-
native strategies for screening from age 15 to death. The analysis
was from the health service perspective.
Screening strategies
We compared current screening protocols using conventional
cytology with five alternative strategies (box). In all strategies,
women with moderate or severe cytology results are referred
directly for colposcopy; inadequate cytology results are retested
(this is assumed to occur immediately); and women with normal
results return to routine screening.
When only cytology was used for repeat testing every six
months (strategies A and E and women aged less than 35 in
strategy D), women were referred for colposcopy after three bor-
derline or two mildly dyskaryotic smear results. Women only
returned to routine screening after three consecutive negative
results, again at six month intervals.
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When cytology and human papillomavirus tests were used
for repeat testing, women were referred for colposcopy if the
repeat test was positive for human papillomavirus, or the
cytology result was mild dyskaryosis or worse, or both, otherwise
they returned to routine screening.
Natural history
From the literature we took the probability of transitions
between health states (healthy, human papillomavirus only,
cervical intraepithelial neoplasia (CIN) grade 1, CIN-2, or CIN-3
and invasive cancer stages I-IV), and the probability of symptoms
in an unscreened population.5 We chose the natural history
model as it has been validated5 and reflects current scientific
understanding of preinvasive disease. Figure 1 illustrates the
health states defined by the model and the potential transitions
between states.
All probabilities of transition were calculated for a six month
time frame, reflecting the cycle length of the model. We adapted
the model for the United Kingdom using local data on survival
from invasive cancer6 and mortality from other causes.7 8 Table 1
shows these and other variables in the model.
We assumed that all cases of preinvasive and invasive cervical
cancer begin with human papillomavirus infection, that the
American categories for low grade and high grade squamous
intraepithelial lesions are equivalent to CIN-1 and CIN-2 or
CIN-3, and that women who survive after five years have the
same life expectancy as women in the general population.15
Attendance
Attendance rates at routine screening were based on the
percentage of eligible women who attended at least once over a
five year period.10 We estimated attendance rates for repeat
screening and colposcopy using data from the pilots.4 We
assumed that if women did not attend they would only be
recalled for screening at the next screening round.
Effectiveness of screening
Estimates of sensitivity and specificity for human papillomavirus
using the hybrid capture II assay were identified from a
meta-analysis.11These studies followed-up women with both
positive and negative test results at colposcopy or histology thus
minimising verification bias. It is assumed that sensitivity and
specificity for human papillomavirus was the same for CIN-1
and only human papillomavirus.
At baseline we used estimates of the sensitivity and specificity
of conventional cytology from an earlier study.16 A recent meta-
analysis emphasised the failure of some trials to meet several
validity criteria but indicated that overall liquid based cytology
shows an 11% (95% confidence interval 3% to 20%)
improvement in sensitivity to detect CIN-1.17 Using the positive
predictive values obtained in the pilots we have estimated an
improvement in the sensitivity of CIN-2 or CIN-3 ranging from
3.6% (95% confidence interval − 1.2% to 5.0%).
Little data exist on the sensitivity of cytology testing and
human papillomavirus testing strategies for the detection of
invasive cancer. We have not modelled in full the screening strat-
egies for invasive cancer, and we have assumed that for all strate-
gies 90% of cases of invasive cancer are detected at each
screening round. All colposcopies were assumed to be 100%
sensitive and specific, and we assumed that all abnormalities
when found at colposcopy are treated. It was assumed that
colposcopic treatment is 90% effective (range 80%-100%),12 and
that 90% (range 0% to 100%) of women return to a healthy state
with no human papillomavirus infection.5
Costs
We used data from the pilot sites to calculate the unit costs of liq-
uid based cytology, conventional cytology, and human papillo-
mavirus testing. Staff time was estimated from record sheets sent
to a random sample of smear takers and all smear readers at the
laboratories. We obtained costs of conventional cytology
equipment and consumables from the laboratory; estimates of
the indicative market price for liquid based cytology and human
papillomavirus equipment were made in consultation with the
NHS Purchasing and Supplies Agency. Unit costs for primary
care were taken from the literature and laboratory staff costs
Alternative strategies for screening women for cervical
cancer
Strategy A
Liquid based cytology only
Strategy B
Combined liquid based cytology and human papillomavirus
testing (hybrid capture II assay for human papillomavirus DNA;
Digene, Abbott, Maidenhead) for women with borderline or
mildly dyskaryotic results. Women who test positive for the virus
are referred for immediate colposcopy and women who test
negative are recalled at six months for repeat cytology and
human papillomavirus testing (this strategy reflects the original
pilot protocol)
Strategy C
Same as strategy B except that women aged less than 35 who
initially tested positive are not referred for colposcopy. Even if
repeat tests for these women give negative results, they are
recalled for a third combined test at 12 months (this strategy
reflects the amended pilot protocol)
Strategy D
Combined liquid based cytology and adjunctive human
papillomavirus testing (as described in strategy B) for women
aged 35 or more, and liquid based cytology only for women
under 35 (as described in strategy A)
Strategy E
Combined liquid based cytology and adjunctive human
papillomavirus testing (as described in strategy B) but no testing
for human papillomavirus in repeat tests
Healthy
Human papillomavirus only
CIN-1
CIN-2 or CIN-3
Stage I
Stage II
Stage III
Stage IV
Fig 1 Natural history of disease model. Death from cervical cancer or from
other causes not shown. CIN=cervical intraepithelial neoplasia
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Table 1 Summary of parameters in cost effectiveness model
Parameters Baseline Minimum Maximum Distribution Reference
Management variables
Yearly (%) discount rate*:
Costs 3.5 0 6 — 9
Effects 3.5 0 6 — 9
Age:
Start of screening 25 —
End of screening 64 —
Screening interval:
Age 25 to 49 3 yearly —
Age 50 to 64 5 yearly —
Attendance (%):
Routine smear 81 76 85  10
Repeat smear (age <35) 79 77 80  4
Repeat smear (age ≥35) 85 84 87  4
Colposcopy (age <35) 95 97 93  4
Colposcopy (age ≥35) 93 90 96  4
Transition probabilities and incidence rates of preinvasive disease (6 months)
Prevalence of human papillomavirus infection age 15† 0.1 5
Prevalence of CIN-1 age 15† 0.01 5
Age specific incidence of human papillomavirus infection: 5
15 to 19 0.051-0.089 5
20 to 23 0.078-0.051 5
24 to 29 0.025 5
30 to 49 0.005 5
≥50 0.003 5
Age specific regression rate, human papillomavirus infection:
15 to 24 0.33 0.26 0.54  5
25 to 29 0.21 0.18 0.26  5
≥30 0.05 0.03 0.07  5
Progression rate (human papillomavirus to CIN-1) 0.04 0.03 0.06  5
Proportion of human papillomavirus infections progressing to CIN-2 or
CIN-3
0.1 0.05 0.5  5
Regression rate CIN-1 to human papillomavirus or healthy:
Age 15 to 34 0.084 0.074 0.126  5
Age ≥35 0.042 0.029 0.074  5
Proportion of CIN-1 reverting to healthy 0.9 0.5 1.0  5
Progression rate CIN-1 to CIN-2 or CIN-3
Age 15 to 34 0.0087 0.0087 0.029  5
Age ≥35 0.035 0.029 0.056  5
Regression rate CIN2/3 to CIN1 or healthy 0.035 0.0292 0.056  5
Proportion of CIN2/3 reverting to healthy 0.5 0 0.5  5
Progression rate CIN2/3 to invasive cancer 0.025 0.018 0.034  5
Effectiveness of screening
Human papillomavirus testing:
Sensitivity 0.948 0.927 0.969 Uniform 11
Specificity 0.673 0.582 0.764 Uniform 11
Effectiveness (%) of colposcopy 90 80 100 Uniform 12
Progression rate stage I to stage II 0.13 — — — 5
Probability of symptoms stage I 0.08 — — — 5
Progression rate stage II to stage III 0.23 — — — 5
Probability of symptoms stage II 0.12 — — — 5
Progression rate stage III to stage IV 0.44 — — — 5
Probability of symptoms stage III 0.37 — — — 5
Probability of symptoms stage IV 0.68 — — — 5
Annual probability of survival after invasive cancer diagnosis‡
Stage I 0.97-0.99  8
Stage II 0.77-0.96  8
Stage III 0.54-0.90  8
Stage IV 0.49-0.88  8
Costs (2001-2 prices)
Conventional cytology† 23.6 23.4 23.8 
Liquid based cytology† 25.7 23.5 28.2 
Human papillomavirus test 20.5 10.3 34.5 
Colposcopy outpatients (no CIN) 122 98 147  13
Colposcopy and treatment for CIN 624 415 833  14
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estimated using the mid-point of staff salaries.18 We adjusted the
costs for cytology to incorporate the cytology results that were
inadequate (that is, where slides were not able to be interpreted
for technical reasons).4 It was assumed that kits to test for human
papillomavirus are used to process a batch of samples at full
capacity. All costs are converted to 2001-2 prices using the NHS
Health and Community Price Index and are reported in sterling.
We used a detailed patient audit of the costs of invasive can-
cer over five years, including treatment and palliative care.14 We
assumed that no additional costs would be incurred beyond this
period.15 We also used audit data on costs associated with cervi-
cal intraepithelial neoplasia, including initial diagnosis at colpos-
copy, management (for example, loop cone biopsy), and any
subsequent colposcopy follow-up (including adverse events).14 A
single outpatient attendance was used as a proxy cost for a
colposcopy when there was no cervical intraepithelial neopla-
sia.13
Analysis
Following current UK recommendations, we discounted future
costs and future benefits at 3.5% for the first 30 years and 3%
thereafter.9 To estimate the comparative cost effectiveness
between the strategies, we first ranked the strategies in ascending
order of effectiveness. We excluded options that were dominated
(that is, less effective and more costly than an alternative) and
strategies that were extended dominated (that is, inside the cost
effectiveness frontier). For the remaining strategies we calculated
the incremental costs, effects, and resulting cost effectiveness
ratios (costs divided by effects).
To test the effect of uncertainty about a variable, we carried
out one way and probabilistic sensitivity analyses. In the one way
sensitivity analysis we used the minimum and maximum
estimates for each variable. As the data for estimating the sensi-
tivity of conventional cytology were based on one UK study, we
used additional data from the international literature to test
uncertainty around these estimates. We carried out a random
effects meta-analysis to synthesise the result of a systematic
review.19 Nine studies were identified that did not have
verification bias and were carried out in routine low risk settings.
The combined estimate of sensitivity to detect CIN-1 was 0.46
(95% confidence interval 0.29 to 0.72) and to detect CIN-2 or
CIN-3 was 0.84 (0.75 to 0.94).
We also undertook a probabilistic sensitivity analysis.20
Appropriate distributions were assigned depending on the avail-
ability of data and type of variable (see table 1). Using simulation,
we generated a series of estimates for the costs and effects of
each strategy by sampling from the distribution of each model
variable. We then used a net benefit framework to plot cost effec-
tiveness acceptability curves showing optimal strategies at differ-
ent values that society would be willing to pay for a gain in life
years (see bmj.com).21
Results
Our model predicted a peak prevalence for human papillomavi-
rus at 22 years of age, tailing off significantly after age 30. The
prevalence for CIN-1 peaks at age 25. The rates of human papil-
lomavirus for women aged 30-60 are consistent with UK data on
human papillomavirus prevalence collected in the HPV in addi-
tion to routine testing trial.22 Allowing for death from other
causes, the model predicts a lifetime risk of death from invasive
cancer of 1.4%. This estimate is consistent with modelling
estimates from a recent study, which predicted that in the
absence of screening the lifetime risk of death from invasive can-
cer was 1.5% for women born after 1950.23
Table 2 reports the baseline point estimates for the cost effec-
tiveness results, which are illustrated in figure 2. Compared with
screening using conventional cytology, the next most cost effec-
tive strategy seems to be combined liquid based cytology and
human papillomavirus testing to prioritise women aged 35 or
more with borderline or mildly dyskaryotic smear results for
immediate colposcopy (strategy D). Although liquid based cytol-
ogy alone (strategy A) is cheaper than strategy D, it also seems
less effective and has a higher cost effectiveness ratio. Therefore
it is likely to be more cost effective to use strategy D.
Strategies B, C, and E (human papillomavirus testing used to
triage women of all ages with borderline or mild results) provide
additional health gain compared with strategy D (human papil-
lomavirus testing restricted to only women aged more than 35)
Parameters Baseline Minimum Maximum Distribution Reference
5 year treatment costs (£) after detection:
Stage I 10 702 9354 12 041  14
Stage II 17 629 14 279 20 982  14
Stage III 17 513 13 880 21 143  14
Stage IV 18 639 8147 29 129  14
CIN=cervical intraepithelial neoplasia.
*3% after 30 years.
†Age specific.
‡Estimates vary by year since diagnosis.
§Includes adjustment for inadequate rates.
Table 2 Baseline estimates of lifetime discounted costs (£) and effects per average women by screening strategy
Screening strategy
Difference compared with conventional cytology* Incremental comparison†
Life years gained
(discounted) Lifetime cost (discounted)
Life years gained
(discounted) Lifetime cost (discounted) Incremental cost effectiveness ratio
A 0.0019 9.9 — — —‡
D 0.0034 12.7 0.0034 12.7 3735
C 0.0039 20.2 — — —‡
E 0.0049 19.1 0.0015 6.4 4233
B 0.0050 19.9 0.0001 0.8 £18 605
*Conventional cytology was least effective strategy.
†Options are compared with next strategy, which was less effective on cost effectiveness frontier.
‡Options that were extended dominated (that is, inside the cost effectiveness frontier) were excluded.
§Compared with conventional cytology
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but are also more expensive. Strategy C is inside the cost
effectiveness frontier and is likely to be dominated (fig 2). These
results suggest that strategy E (no human papillomavirus testing
in surveillance) may save slightly less life years but is also slightly
less expensive than strategy B (combined human papillomavirus
testing and cytology in surveillance).
Lifetime resource use and invasive cancer mortality
Table 3 reports estimated lifetime use of resources and mortality
from invasive cancer. Compared with screening using only liquid
based cytology, there is a 52%-86% reduction in the number of
surveillance smears required with the four strategies using
human papillomavirus testing.With such strategies, however, the
average number of lifetime colposcopies is increased by between
64% and 138%. This increase in referral for colposcopy is lowest
when only women aged more than 35 are tested for human pap-
illomavirus. A clear trade-off exists between reduced repeat sur-
veillance smears and increased referral for colposcopy.
The baseline model predicts a 0.49% lifetime risk of death
with liquid based cytology, which compares with current UK data
of a 0.56% lifetime risk of death from invasive cancer.7 The
model predicts that for women with a borderline result from a
routine smear test, 67% aged less than 35 and 50% aged 35 or
more would test positive for human papillomavirus, and that for
women with a mild test result, 81% aged less than 35 and 67%
aged 35 or more would test positive. These data are similar to
those in the findings of the pilot sites.4
Sensitivity analyses
In the one way sensitivity analysis the ranking of the strategies
remained similar. The costs associated with liquid based cytology,
human papillomavirus testing, and colposcopy had a significant
influence on the overall costs. Key areas of uncertainty in the
model were the extent preinvasive cancer developed to high
grade disease and the sensitivity of cytology for detecting under-
lying CIN-2 or CIN-3. When the sensitivity of cytology is
increased, human papillomavirus testing seems to be less
effective, particularly for surveillance of women with initial nega-
tive results for human papillomavirus (see bmj.com).
Figure 3 illustrates the results of the probabilistic analysis
(strategy C was excluded as it was dominated, strategy B is not
shown but almost overlaps strategy E) and shows that with the
current level of evidence there is considerable uncertainty in
both the incremental costs and incremental gains that would
accrue from using human papillomavirus testing as a triage for
women with borderline or mildly dyskaryotic smear results. A
negative correlation also exists in the human papillomavirus
triage strategies between costs and effects. Finally, the cost effec-
tiveness acceptability frontier shows that if a decision maker is
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Fig 2 Incremental discounted lifetime costs and effects of alternative screening
strategies for cervical cancer compared with screening using conventional
cytology only
Table 3 Estimates of average lifetime resource use, risk of treatment for invasive cancer, and mortality
Lifetime resource use
Strategy
A B C D E
Average No of routine smears 9.4 9.4 9.4 9.4 9.4
Average No of smears in surveillance 0.77 0.11 0.24 0.37 0.30
Average No of human papillomavirus tests after initial routine
smear
0.00 0.42 0.43 0.25 0.40
Average No of human papillomavirus tests in surveillance 0.00 0.11 0.21 0.08 0.00
Average No of colposcopies 0.21 0.41 0.40 0.31 0.35
Average lifetime probability of treatment for invasive cancer 0.02 0.017 0.013 0.013 0.013
Lifetime risk of death from invasive cancer 0.0049 0.0045 0.0046 0.0046 0.0045
Incremental life years gained (discounted)
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Fig 3 Results of probabilistic sensitivity analysis. Ellipses show 95% confidence interval for each strategy
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willing to pay between £7500 (€11 100; $13 000) and £30 000
per life year gained, strategies when human papillomavirus test-
ing is added to liquid based cytology screening to prioritise all
women with borderline or mild dyskaryotic smear results for
immediate colposcopy give the greatest net health benefit (see
figure on bmj.com).
Discussion
Using human papillomavirus testing to triage women with mild
or borderline cervical smear results is more expensive than
repeat cytology but saves slightly more lives. This gain in life
expectancy is related both to referring women earlier to colpos-
copy and to minimising loss to follow up after the initial smear
result. This is consistent with the baseline results from a UK
study.24 Our results can also be compared with a US study, which
showed that human papillomavirus testing to triage women with
borderline smears saved slightly more lives but was not as
expensive as the other screening strategies.25
Our study provides further analysis of the alternative
strategies for adding human papillomavirus testing. It suggests
that the most likely strategy to be cost effective (if society is will-
ing to pay between £7500 and £30 000 per life year) uses human
papillomavirus testing to triage all women with an initial border-
line and mild smear result, using cytology to follow-up women
only with a negative test result for human papillomavirus.
As with these previous models we used a Markov modelling
approach. In this paper we also explored the uncertainty in the
model’s variables using a probabilistic sensitivity analysis.
Alternative modelling approaches exist such as discrete event
simulation using individual patient transitions—the advantage of
moving to this more complex framework given the lack of avail-
ability of patient level data on the natural history is unclear.26
The predicted substantial increase in lifetime referral for col-
poscopy with human papillomavirus testing is of concern (table
3). This finding is confirmed by the observed 12 month
outcomes in the pilot study and by the other cost effectiveness
model for the United Kingdom.24 Nevertheless our conclusions
on the cost effectiveness of human papillomavirus testing are
robust in the sensitivity analyses when the estimates for cost and
effectiveness of colposcopy are varied. Although we have
explored a range of screening strategies, further potential
options exist such as referring all women with mild cytology
results directly to colposcopy or primary human papillomavirus
testing.
Finally, this study is limited by the lack of data on the quality
of life implications and societal costs (for example, cost of wom-
en’s time attending for surveillance smears and colposcopies) of
using human papillomavirus testing to triage women compared
with repeat testing. A trade-off exists between the predicted
potential gains in life expectancy and reduction in surveillance
smears (52%-86%) using human papillomavirus testing, and the
negative implications for women of increased lifetime colpo-
scopies (64%-138%). This deserves careful consideration and
further research.
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